Pool J L, Kirby R S
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Int Urol Nephrol. 2001;33(3):407-12. doi: 10.1023/a:1019504703485.
Alpha1-adrenoceptor antagonists have been shown to provide effective relief from symptoms of benign prostatic hyperplasia (BPH) with attendant improvements in quality of life. Although the alpha1A-adrenoceptor subtype predominates over other subtypes of alpha1 adrenoceptors in the prostate gland, there is no evidence that a subselective alpha-adrenoceptor antagonist provides a clinical advantage over a selective alpha1-adrenoceptor antagonist in the treatment of patients with BPH. The pharmacokinetic profiles of alpha1A-adrenoceptor antagonists and their documented penetration of the blood-brain barrier (CNS adverse effects) preclude a clinical benefit of subselective alpha-adrenoceptor blockers over selective alpha1 blockers.
α1肾上腺素能受体拮抗剂已被证明能有效缓解良性前列腺增生（BPH）的症状，并随之改善生活质量。尽管α1A肾上腺素能受体亚型在前列腺中比其他α1肾上腺素能受体亚型占主导地位，但没有证据表明在治疗BPH患者时，亚选择性α肾上腺素能受体拮抗剂比选择性α1肾上腺素能受体拮抗剂具有临床优势。α1A肾上腺素能受体拮抗剂的药代动力学特征及其已被证实的血脑屏障穿透性（中枢神经系统不良反应）排除了亚选择性α肾上腺素能受体阻滞剂相对于选择性α1阻滞剂的临床益处。
